---

Arlene E. Maurice, PA-C
Urology

EDUCATION

Graduated - September 2008	Midwestern University, IL - Master’s of Medial Science
Graduated - May 2004	Iowa State University - Bachelor’s of Science in Biology

CERTIFICATES AND LICENSES:

Drug Enforcement Agency Registration, November 2008

Arizona Regulatory Board of Physician Assistants, February 2010

NCCPA Certified Physician Assistant, September 2008

American Heart Association, BLS and ACLS, July 2009/August 2009

RESEARCH EXPERIENCE

A randomized, Placebo-controlled, Double-Blind, Parallel Design, Phase 3 Study to Assess the Safety and Efficacy of XXXXX Tablets in Male Subjects with Erectile Dysfunction

An Open-Label Phase 3 Study to Evaluate the Long-Term Safety and Efficacy of XXXXX of Tablets in Male Subjects with Erectile Dysfunction

A Multi-Center, Randomized, Double Blind, Parallel Group Evaluation of Effectiveness and Safety of XXXXXXX Compared to Inactive Vehicle Control of Subjects with Interstitial Cystitis/ Painful Bladder Syndrome (IC/PBS)

Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of XXXXX in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer

A Randomized, Controlled, Open-Label of Trial XXXXX Intermittent Therapy Vs. Continuous Androgen Deprivation Therapy with XXXXX or XXXX in Patients with Carcinoma of the Prostate with Biochemical Failure after Localized Therapy

A 12-Week Randomized, Double-Blind Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of XXXXX Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder

A Phase III, Randomized, Double-Blind Placebo-Controlled, Parallel Group, Placebo Controlled, Multicenter to Study to Assess the Efficacy and Safety of the Beta-3 Agonist XXXX in Subjects with Symptoms of Overactive Bladder

A Randomized, Double-Blind, Parallel Group, Active Controlled, Multicenter, Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist XXXX (50mg QD and 100mg QD) in Subjects with Symptoms of overactive Bladder

A Phase iii, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Beta-3 Agonist XXXX (25mg QD and 50mg QD) in Subjects with Symptoms of Overactive Bladder